Making ready-made CAR T cells for cancer immunotherapy
A new technique enables the production of generic CAR T cells at scale, making CAR T-cell immunotherapy more accessible to patients with cancer. (Images: AdobeStock, Illustration: Sebastian Stankiewicz/Boston Children’s Hospital) In CAR T-cell immunotherapy, T cells from a patient’s own blood are engineered to carry so-called chimeric antigen receptors (CAR)
